Roche's Second Reinvention: Beyond Oncology into Obesity, IBD, and Cell Therapy
核心洞察
Roche has deployed over $15 billion in upfront capital across roughly two years to enter obesity (搜索), inflammatory bowel disease, allogeneic cell therapy, and neurodegeneration, marking a strategic pivot beyond its traditional oncology base.
The company's TL1A (搜索) antibody afimkibart (搜索), acquired via the $7.1 billion Telavant (搜索) deal, faces intensified competition after Merck (搜索)'s tulisokibart delivered the first positive phase 3 results in ulcerative colitis (搜索) in June 2026.
Roche's obesity (搜索) strategy centers on CT-388, a dual GLP-1/GIP (搜索) agonist showing 22.5% placebo-adjusted weight loss at 48 weeks, combined with Zealand Pharma's amylin (搜索) analog petrelintide in a $5.3 billion collaboration.
Roche, the Swiss pharmaceutical giant that once dominated global oncology with its Genentech-derived trio of Herceptin, Avastin, and Rituxan, is now executing what may be its most ambitious strategic pivot in decades. Since 2023, the company has committed well over $15 billion in upfront capital to enter obesity (搜索), inflammatory bowel disease (IBD), allogeneic cell therapy, and neurodegeneration — therapeutic areas far removed from the cancer franchise that built its commercial identity.
The scale and speed of this transformation reflect a deliberate response to a changed competitive landscape. Once the world's largest oncology company by sales, Roche has slipped down the rankings as rivals such as Merck (搜索) and AstraZeneca have expanded rapidly with immunotherapies and targeted delivery systems. "Roche was a standout success story and revolutionised cancer treatment," said Beat Wittmann, founder of Swiss corporate advisory group Porta Advisors. "But it has struggled to remain a leader."
The Biosimilar Cliff and the First Reinvention
Roche's current repositioning follows an earlier crisis that the company navigated successfully. Its three oncology blockbusters — Herceptin, Avastin, and Rituxan — collectively generated around $21 billion in annual sales at their peak. When biosimilars arrived, the erosion came harder and faster than anticipated. By Q1 2022, Avastin had shed 32% of its sales year-on-year, Herceptin 19%, and Rituxan 21%. The CHF 9.6 billion ($11.8 billion) sales gap the company had modeled between 2018 and 2023 was crossed by 2021.
Roche grew through it. A new generation of medicines — Ocrevus in multiple sclerosis, Hemlibra in hemophilia, Vabysmo in retinal disease, Phesgo, and Xolair — absorbed the hit. By 2025, these five growth drivers generated combined sales of CHF 21.4 billion ($26.4 billion), up CHF 3.2 billion from 2024. Ocrevus, an anti-CD20 antibody approved in 2017, became Roche's biggest seller at CHF 7.01 billion ($8.6 billion). Hemlibra reached CHF 4.8 billion ($5.9 billion), up 11% year-on-year.
The Obesity (搜索) Bet: CT-388 and the Combination Strategy
Roche's most audacious expansion is into obesity (搜索), where the lead asset is CT-388, a once-weekly injectable dual GLP-1/GIP (搜索) receptor agonist — the same mechanistic class as Eli Lilly's Zepbound. In January 2026, Roche published phase 2 data showing placebo-adjusted weight loss of 22.5% at 48 weeks at the highest dose tested, without reaching a plateau. Two phase 3 trials are now underway, initiated in Q1 2026.
The timing presents challenges. CT-388 enters phase 3 at a point when Wegovy and Zepbound already have years of commercial infrastructure and physician familiarity behind them. Roche's answer is a combination strategy. The company is betting that by the time it arrives, combinations addressing tolerability limitations — particularly nausea-driven discontinuation and concerns about muscle mass loss — will be the new standard.
Central to this thesis is petrelintide, an amylin (搜索) analog acquired via a $1.65 billion upfront collaboration with Zealand Pharma, against a total potential value of $5.3 billion. Petrelintide is designed to complement GLP-1 therapy by reducing nausea and preserving lean mass, with a combination study with CT-388 planned for the first half of 2026. However, not all bets have survived: in March 2026, Roche discontinued Emugrobart, an anti-myostatin antibody meant to address lean mass preservation.
Teresa Graham, head of Roche Pharmaceuticals, has argued the market remains too focused on "shock-and-awe numbers," suggesting the Zealand treatment's tolerability could make it useful in combinations or longer-term weight maintenance.
The $7.1 Billion TL1A (搜索) Wager and a Crowded Field
In October 2023, Roche acquired Telavant (搜索) for $7.1 billion upfront plus a $150 million near-term milestone, securing U.S. and Japan rights to afimkibart (搜索), an anti-TL1A (搜索) antibody with phase 2b data in ulcerative colitis (搜索). TL1A is distinct from most existing IBD targets because it drives both immune activation and fibrosis — the scarring that causes long-term complications in Crohn's disease (搜索).
The TL1A (搜索) space, however, has become one of the most crowded in immunology. Merck (搜索), Sanofi/Teva, AbbVie, Spyre Therapeutics, and Boehringer Ingelheim are all pursuing the target. In June 2026, Merck announced that its TL1A antibody tulisokibart had delivered the first positive phase 3 results in ulcerative colitis (搜索), beating Roche to the clinical milestone. Roche's regulatory filing for afimkibart (搜索) is expected in 2027, meaning it will likely be a second or third entrant — a different commercial proposition than the $7.1 billion price tag anticipated.
Cell Therapy: The Poseida Platform
The November 2024 acquisition of Poseida Therapeutics for up to $1.5 billion gives Roche a credible allogeneic CAR-T platform. Current autologous CAR-T therapies require manufacturing from each patient's own cells — a time-consuming, expensive, and logistically complex process. Allogeneic therapies use donor cells manufactured in advance, enabling faster access and potentially lower costs.
Poseida's lead candidate, P-BCMA-ALLO1, targeting multiple myeloma (搜索), demonstrated a 91% overall response rate in phase 1 data in heavily pretreated patients. The platform also has applications in autoimmune disease, an area of growing interest for the CAR-T field.
Neuroscience: Trontinemab and the Brainshuttle
Roche has a painful history in neurodegeneration, with gantenerumab failing in phase 3 Alzheimer's trials in 2022, following earlier setbacks with crenezumab. Trontinemab, its next Alzheimer's candidate, employs Roche's proprietary Brainshuttle technology to carry the antibody across the blood-brain barrier via the transferrin receptor, achieving faster and deeper amyloid (搜索) clearance than prior antibodies. Phase 2 data showed 91% of participants became amyloid PET-negative after six months. Two phase 3 trials have been initiated, with results expected by 2028.
The Brainshuttle platform has been described by a Roche insider as "one of the biggest wild cards." Early studies suggest the approach has the potential to remove almost all protein plaques linked to Alzheimer's while reducing dangerous side effects such as brain swelling. Roche is also developing blood tests designed to detect Alzheimer's earlier, potentially before severe symptoms appear.
In Parkinson's disease (搜索), the phase 2 Padova trial of prasinezumab missed its primary endpoint, but Roche has committed to phase 3, citing that the totality of data suggests the drug could be the first disease-modifying candidate — a defensible call given the near-total absence of disease-modifying options.
Financial Discipline and Pipeline Rationalization
CEO Thomas Schinecker, who took the helm in 2023, has reshaped the company's strategy. Research has been narrowed to five core therapeutic areas, with stricter hurdles for drug development and a more selective approach to acquisitions. Stefan Frings, deputy chief medical officer, described the R&D overhaul as an effort to "be fast, cost-efficient and have a high rate of successful trials."
At the JPMorgan Healthcare Conference in January 2025, Graham said Roche has roughly $10 billion in M&A firepower it can deploy each year. The estimated value of its drug pipeline has risen 63% since 2022, and a record number of medicines are entering late-stage development.
Some analysts see recovery. Citi wrote this year that it believed Roche's drug portfolio had "turned a corner," while James Gordon of Barclays said the company still offered a "strong medium- to long-term growth outlook." Yet Jefferies analyst Michael Leuchten cautioned that excessive cost discipline could hurt innovation: "At some point you might find that you're squeezing out the one project that might end up working."
The recovery, according to Vontobel analyst Stefan Schneider, remains a "show me" story for many investors, with several key drugs still needing to prove they can generate commercial success, not just promising trial results. As one of Roche's big U.S. investors put it, "you're often only one or two major drugs away from returning to the top."